I
n accordance with the results of the Age-Related Eye Disease Study (AREDS), 1 a randomized controlled trial performed in the United States, patients with age-related macular degeneration (AMD) in the United States have been instructed to take micronutrient supplements when their lesion fits the inclusion criteria. 2 We conducted a survey about the patients' supplement use and the ophthalmologists' attitudes toward supplements in Japan, where the use is not based on ophthalmologists' prescription.
Methods. The questionnaire was given to patients diagnosed as having AMD at the Medical Retina Division, Department of Ophthalmology, Keio University Hospital, Tokyo, Japan, between January 8, 2010, and June 25, 2010. Another questionnaire was given to the ophthalmologists in our department. Supplements containing more than 50% of the AREDS-recommended levels of vitamin C, vitamin E, and zinc were designated AREDS-like supplements, and those that contained reduced amounts of beta carotene and included lutein were designated AREDS plus lutein supplements. This study was approved by the ethics committee of the Keio University School of Medicine. (Table) , 48 (34.5%) used an AREDS-related supplement under their ophthalmologists' instruction; 17 used an AREDS-like supplement and 31 used an AREDS plus lutein supplement. Ninety-one participants (65.5%) had not used a supplement (Table) , of whom 61 (43.9%) had not been given any instruction.
Doctor Survey. All of the 6 retinal specialists and 11 of the 12 non-retinal-specialized ophthalmologists considered AREDS-like supplements effective. All of the retinal specialists and 10 non-retinal-specialized ophthalmologists instructed their patients based on AREDS. However, 5 retinal specialists and 3 of the others included some additional information.
Comment. Overall, 56.6% of the participants in this study were taking supplements, which is lower than the proportion reported in the United States (93%).
2 Surprisingly, all of the candidates who used the supplements were instructed to do so by ophthalmologists, suggesting that the patients' main source of information about supplements was their ophthalmologists. In this study, only 34.5% of the candidates used AREDS-related supplements, which is far lower than in the previous report in the United States (67%). This was in contrast to the high level of adherence among the candidates (48 of 78 participants [61.5%]; no significant difference according to age or sex). It should be noted that the instruction rate of the ophthalmologists was more critical than the adherence rate of the patients for taking supplements. Interestingly, AREDS plus lutein supplements were used more often than AREDS-like supplements in this study, in contrast to a US-based study. 2 A recent survey in a Japanese cohort reporting the protective association of the serum levels of carotenoids with AMD 3 and studies in animal models showing the tissue-protecting effects of lutein as a bluelight filter and antioxidant 4, 5 may have promoted the use of AREDS plus lutein supplements.
The ophthalmologists did not always recommend supplements in accordance with AREDS. Some ophthalmologists were not completely confident that the AREDS results are applicable to Japanese or other Asian patients with AMD because of the differences in the clinical features of Asian and white patients with AMD. 2, 6 The increased incidence of AMD and the resulting vision loss are now serious issues. Preventive therapy is important for both patients' personal health and their continued contributions to society. Reliable evidence based on a randomized controlled trial is still needed for ophthalmologists to appropriately instruct patients' use of supplements to prevent the progress of AMD in Japan.
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